We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Completes Acquisition of Controlling Majority Stake in RSIPL
News

Evotec Completes Acquisition of Controlling Majority Stake in RSIPL

Evotec Completes Acquisition of Controlling Majority Stake in RSIPL
News

Evotec Completes Acquisition of Controlling Majority Stake in RSIPL

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Completes Acquisition of Controlling Majority Stake in RSIPL"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG has announced that the acquisition of the controlling majority stake of Research Support International Private Limited (RSIPL) has been successfully completed and that RSIPL is a 70%, majority owned subsidiary of Evotec as of August 31, 2009.

The purchase price for the 70% controlling majority stake payable, before adjustments, to DIL Limited, India, is EUR 2.8 million in cash, a portion of which includes a potential earn-out. Evotec has a call option to purchase the remaining 30% from DIL in the future in the event of a change of control.

Following the transaction, RSIPL will be integrated, into the value chain of Evotec's operations in Hamburg (Germany), Abingdon (UK) and Singapore. The members of the Management Board of Evotec AG, Dr Werner Lanthaler, Dr Mario Polywka and Dr Klaus Maleck, have been appointed as members of the Board of Directors of Evotec India together with two representatives from DIL.

This transaction represents an important capacity expansion for Evotec. It adds a complementary drug discovery operation and capability in the field of science-driven chemistry work in India to Evotec's discovery platform and increases its ability to deliver high quality, know-how driven drug discovery and development services to its partners on a global scale.
Advertisement